Pharma: Other News To Note
Wednesday, March 7, 2012
Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for review a resubmission of a new drug application for perampanel (E2007) for partial onset seizures of epilepsy. Perampanel is an oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor antagonist.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.